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Abstract
Alcoholic hepatitis (AH) frequently progresses to multiple organ failure (MOF) and death. 
However, the driving factors are largely unknown. At admission, patients with AH often show 
criteria of systemic inflammatory response syndrome (SIRS) even in the absence of an infection. 
We hypothesize that the presence of SIRS may predispose to MOF and death. To test this 
hypothesis, we studied a cohort including 162 patients with biopsy-proven AH. The presence of 
SIRS and infections was assessed in all patients, and multivariate analyses identified variables 
independently associated with MOF and 90-day mortality. At admission, 32 (19.8%) patients were 
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diagnosed with a bacterial infection, while 75 (46.3%) fulfilled SIRS criteria; 58 patients (35.8%) 
developed MOF during hospitalization. Short-term mortality was significantly higher among 
patients who developed MOF (62.1% versus 3.8%, P <0.001). The presence of SIRS was a major 
predictor of MOF (odds ratio = 2.69, P=0.025) and strongly correlated with mortality. 
Importantly, the course of patients with SIRS with and without infection was similar in terms of 
MOF development and short-term mortality. Finally, we sought to identify serum markers that 
differentiate SIRS with and without infection. We studied serum levels of high-sensitivity C-
reactive protein, procalcitonin, and lipopolysaccharide at admission. All of them predicted 
mortality. Procalcitonin, but not high-sensitivity C-reactive protein, serum levels identified those 
patients with SIRS and infection. Lipopolysaccharide serum levels predicted MOF and the 
response to prednisolone.
Conclusion—In the presence or absence of infections, SIRS is a major determinant of MOF and 
mortality in AH, and the mechanisms involved in the development of SIRS should be investigated; 
procalcitonin serum levels can help to identify patients with infection, and lipopolysaccharide 
levels may help to predict mortality and the response to steroids.
Alcoholic hepatitis (AH) is one of the most deadly conditions in hepatology. In severe cases, 
patients often develop multiple organ failure (MOF), and the 3-month mortality rate remains 
very high (25%–40%).1 Unfortunately, many patients do not respond to medical treatment, 
and there is an urgent need to develop new pathophysiologically oriented therapies.2 
Identifying the main determinants of MOF and death in these patients could help in the 
development of new targeted therapies.
The mechanisms leading to early death in patients with AH are largely unknown. The degree 
of liver failure and the development of renal failure are associated with a poor outcome.3 In 
patients with acute-onchronic liver failure, mortality is not only due to endstage liver failure 
but often related to MOF.4 We recently found that the development of acute kidney injury 
(AKI) is an early prognostic factor of mortality in AH.5 In this study, we observed that the 
presence of systemic inflammatory response syndrome (SIRS) at admission may have an 
important role in the development of AKI. Moreover, SIRS has recently been associated 
with poor prognosis in patients with acute-onchronic liver failure.4
The prevalence of SIRS in patients with AH and its impact on the development of MOF and 
mortality are unknown. In the setting of AH SIRS may be related to a bacterial infection 
(sepsis); around 25% of patients with AH present with a bacterial infection at admission.6 
However, many patients with AH show features of SIRS (e.g., leukocytosis, fever) without 
any identifiable bacterial infection. In these patients SIRS may be secondary to sterile 
inflammation, namely, an inflammatory response in the absence of pathogens.7 In the liver 
of patients with AH, there is a marked overexpression of proinflammatory cytokines such as 
interleukin-8 and chemokine (C-C motif) ligand 20.8,9 The serum levels of both cytokines 
correlate with short-term mortality, suggesting that inflammatory mediators produced by the 
injured liver play a role in the development of SIRS in patients with AH. In the current 
study, we tested the role of SIRS in the prognosis of patients with AH and the specific roles 
of SIRS with and without infection.
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A critical clinical issue in patients with AH is differentiating between infection-associated 
SIRS and SIRS in the absence of infection. While in some patients infections can be 
diagnosed early based on clinical, radiological, and biochemical criteria (e.g., spontaneous 
bacterial peritonitis or pneumonia), other patients have a positive culture identified after 2–3 
days. Administering broad-spectrum antibiotics in patients under prednisolone therapy and 
with SIRS without infection may be unnecessary, and recent reports have shown that broad-
spectrum antibiotics can favor severe fungal infections.10 Therefore, a secondary aim of our 
study was to identify serum markers capable of distinguishing between SIRS with and 
without infection. We selected a panel of biomarkers associated with systemic inflammation 
and infections in patients with cirrhosis including high-sensitivity C-reactive protein 
(hsCRP), procalcitonin, and lipopolysaccharide (LPS).11–13
Patients and Methods
Patients and Interventions
Data on 162 consecutive patients admitted to the Liver Unit (Hospital Clinic, Barcelona, 
Spain) between the years 2000 and 2012 with biopsy-proven AH were analyzed 
retrospectively. The diagnostic criteria of AH have been described in detail.3 According to 
our center’s clinical protocol, all patients with clinically suspected AH underwent a liver 
biopsy. Only those patients with histologically confirmed AH were included in the analysis, 
which accounted for 76.4% of the patients with clinical suspicion of AH. In all patients, the 
liver biopsy was performed within the first 48 hours of hospitalization and before steroid 
treatment was initiated. Patients with hepatocellular carcinoma or any other potential cause 
of liver disease were excluded from the study. Patients with severe AH, defined as 
Maddrey’s discriminant function (DF) >32 and/or age, bilirubin, international normalized 
ratio, creatinine (ABIC) score >6.71 at admission, were treated with prednisone orally for 4 
weeks, followed by a 2-week taper period, with or without treatment discontinuation in 
nonresponding patients assessed by the Lille model, according to the center’s guidelines 
enforced at the patients’ admission. All patients underwent bacterial infection screening at 
admission, consisting of a chest X-ray, urine and ascitic fluid analysis and cultures, and 
blood cultures, even in the absence of signs of infection, according to the clinical protocol of 
diagnosis and management of AH. In the absence of an identifiable septic focus, patients 
with SIRS did not systematically receive antibiotic treatment, unless the temperature was 
above 38°C. These last patients were considered as infected for the present study. All 
patients in the cohort were followed until 90 days from admission or death. The study was 
approved by the Ethics Committee of the Hospital Clinic, and all patients gave written 
informed consent.
Definitions
The presence of SIRS was evaluated early after patients’ admission, before any therapeutic 
procedure was performed, following the recommendations of the American College of Chest 
Physicians/Society of Critical Care Medicine Consensus Conference (Supporting Table 
S1).14 Infection-associated SIRS was defined as SIRS secondary to a bacterial infection 
(sepsis), present at the patient’s admission. Infections were diagnosed by clinical, 
biochemical, radiological, and/or microbiological criteria. Infections at admission were 
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defined as those infections present at the patient’s admission or diagnosed within the first 48 
hours of hospitalization. Infections diagnosed later in the patient’s hospitalization were 
considered in-hospital infections. In order to define single organ failure and MOF, the 
Sequential Organ Failure Assessment (SOFA) score15 was used. Single organ failure was 
defined as a score of 3 or more in a given organ according to the SOFA16 at any time during 
hospitalization. Minor modifications were incorporated to reflect the impact of specific AH 
prognostic factors such as Maddrey’s DF,17 AKI,5 and hepatic encephalopathy2 on survival 
in AH (Table 1). Multiple organ failure was considered when failure of two or more organs 
was present.
The response to corticosteroids was assessed at 7 days using the Lille score.18 Patients 
presenting a score <0.45 were considered responders to corticosteroids, while patients with a 
score ≥0.45 were considered nonresponders.
Determination of hsCRP, Procalcitonin, and LPS Serum Levels
Serum samples were obtained from peripheral blood at the time of the transjugular liver 
biopsy and stored at −80°C. The serum concentration of hsCRP was determined by particle-
enhanced immunoturbidimetry using CardioPhase reagent (Siemens Healthcare Diagnostics, 
Inc., Tarrytown, NY). Procalcitonin serum concentration was determined through an 
automated immunofluorescence assay in a Kryptor analyzer (Brahms, GmbH, Hennigsdorf, 
Germany). Serum levels of LPS were determined using the limulus amebocyte lysate 
QCL-1000 test (Lonza Walkersville, Inc., Walkersville, MA).
Statistical Analysis
Continuous variables were described by mean (95% confidence interval [CI]). Categorical 
variables were described by means of counts and percentages. Comparisons between groups 
were performed using the Student t test or Mann-Whitney U test when appropriate. 
Differences between categorical variables were assessed by the chi-squared test or Fisher’s 
exact test. The main endpoints were development of MOF during hospitalization and 90-day 
mortality. In the multivariate analysis of factors associated with MOF and mortality, only 
those that were statistically significant (P<0.05) at the univariate analysis were entered into 
a multivariate logistic or Cox regression. The P values for the univariate tests were not 
corrected for multiple testing because those tests were taken as exploratory. The results of 
the multivariate logistic or Cox regression analysis (odds ratio [OR] or hazard ratio) 
identified those variables independently associated with the main outcome (after adjusting 
for the contributions of other variables). A P value <0.05 was required for significance. To 
avoid overfitting of the models, a predefined ratio of candidate prognostic variables to the 
number of observed events (MOF or deaths) was set at 1:10 or less. Receiver operating 
characteristic curves were created and compared to assess the prognostic performance of AH 
prognostic scores and inflammatory biomarkers. The SPSS statistical package (version 18.0; 
SPSS, Inc., Chicago, IL) was used for all analyses.
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Demographic, clinical, and biochemical characteristics of patients with AH are listed in 
Table 2. Clinical, radiological, and/or histological criteria of liver cirrhosis were present in 
72.8% of the patients. A bacterial infection was identified in 19.8% of the patients at 
admission, while 43.8% of the patients developed in-hospital infections. A detailed 
description of the type of infections and their impact on mortality in the global cohort and 
among patients treated with steroids is provided in the Supporting Information. A summary 
of the outcome of the patients according to the presence of SIRS and infections is shown in 
Supporting Fig. S1.
MOF: Incidence, Predictive Factors, and Impact on Mortality
Thirty-six percent of the patients developed MOF during the hospitalization. The organs 
most frequently involved were the liver and the kidney (70.8% and 34% of patients, 
respectively), while circulatory failure was present in 10.6%, coagulopathy in 9.3%, 
respiratory failure in 6.8%, and neurological failure in 6.2% (Supporting Fig. S2). Thirty-
seven patients (22.8%) presented no organ failure, while 67 patients (41.4%) presented one 
organ failure, 34 patients (21%) presented two organ failure, and 24 (14.8%) presented three 
or more organ failure (Supporting Fig. S3A). As expected, 90-day mortality was 
significantly higher in patients who developed MOF (62.1% versus 3.8% in patients with 
and without MOF, respectively; P<0.001) (Fig. 1A). Mortality according to the number of 
organs failing is shown in Supporting Fig. S3B. The association of MOF with mortality was 
independent of the degree of liver dysfunction, as assessed by the ABIC or Model for End-
Stage Liver Disease (MELD) score, Maddrey’s DF, and the Lille score. The performance of 
existing predictive scores in predicting MOF in patients with AH is shown in the Supporting 
Information.
Patients who developed MOF had a more severe liver dysfunction and were more likely to 
fulfill SIRS criteria (60.3% versus 38.5%, P=0.007) or present with a bacterial infection at 
admission (31% versus 13.5%, P=0.007) or during hospitalization (77.6% versus 25%, 
P<0.001) (Table 3). Variables associated with the development of MOF in the univariate 
analysis are depicted in Table 4. In a logistic regression multivariate analysis (Table 4), the 
variables that independently predicted MOF were the presence of SIRS at admission 
(OR52.687, P=0.025), serum creatinine (OR=2.508, P=0.021), and serum bilirubin 
(OR=1.096, P<0.001). These results strongly indicate that SIRS is a major determinant in 
the development of MOF in patients with AH. When included in the analysis, the presence 
of in-hospital infections showed a powerful association with MOF (OR=6.585, P<0.001), 
while SIRS and bilirubin levels at admission maintained a statistically significant 
association. While the presence of cirrhosis (F4) did not predict the development of MOF 
and death, the presence of chronic liver failure criteria of acute-onchronic liver failure4 
strongly predicted these unfavorable outcomes. These results are described in detail in the 
Supporting Information.
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SIRS: Associated Conditions and Impact on Patient Outcome
We studied the characteristics and role of SIRS as it is a strong clinical predictor of MOF. 
Nearly half of the patients with AH (46.3%) fulfilled SIRS criteria at admission (Table 5). 
There were no differences in the prevalence of SIRS according to the severity of AH. 
Patients with SIRS criteria showed a higher prevalence of infection at admission (30.7% 
versus 10.3% with and without SIRS, respectively; P=0.001), while the incidence of 
inhospital infections was comparable between patients with and without SIRS (46.7% versus 
41.4%, P=0.499). The presence of SIRS at admission did not predict the response to 
corticosteroids (Table 5). Importantly, the presence of SIRS at admission negatively 
impacted patients’ outcome. Overall 90-day mortality was significantly higher among 
patients with SIRS at admission (36% versus 14.9% in patients with and without SIRS, 
respectively; P=0.002) (Fig. 1B), independently of the degree of liver dysfunction and the 
Lille score in patients treated with corticosteroids (Supporting Table S2). The area under the 
receiver operating characteristic curve of SIRS for the prediction of 90-day mortality was 
0.641 (95% CI 0.543–0.739), while the area under the receiver operating characteristic curve 
of the ABIC and MELD scores and Maddrey’s DF was 0.817 (95% CI 0.749–0.885), 0.815 
(95% CI 0.744–0.886), and 0.714 (95% CI 0.623–0.805), respectively (Supporting Fig. S4). 
The prognostic performance of the individual SIRS criteria is described in the Supporting 
Information. Moreover, patients with SIRS criteria showed a higher incidence of MOF 
during hospitalization than patients without SIRS (46.7% versus 26.4%, P=0.007) (Table 5), 
also independently of the ABIC score, MELD score, Maddrey’s DF, and the Lille score 
(Supporting Table S2). The association of SIRS with mortality was also independent of the 
presence of hepatic encephalopathy, which was found to be an important prognostic factor 
of mortality in our study (more details are provided in the Supporting Information).
Of the 75 patients with SIRS at admission, only 30.7% were diagnosed with an infection. 
Baseline characteristics of patients with SIRS with and without infection were comparable 
(Table 5). Mortality at 90 days was similar in patients with infection-associated SIRS and 
SIRS without infection (39.1% and 34.6%, respectively; P=0.503) and much higher than in 
patients without SIRS (14.91%, P<0.01 for both) (Fig. 1C). There was a clear trend toward 
an earlier death in patients with infection-associated SIRS compared to patients with SIRS 
without infection, with the maximum difference observed on day 30 from admission. When 
30-day mortality was compared, borderline significance was found (30-day mortality 39.1% 
in infection-associated SIRS versus 19.2% in SIRS without infection, P = 0.057). Similarly, 
both causes of SIRS equally predicted MOF (42.3% in patients with SIRS without infection 
and 56.5% in patients with infection-associated SIRS, P = 0.255) (Table 5). These results 
indicate that regardless of the origin, patients with SIRS are at high risk for developing MOF 
and early death.
Serum Biomarkers in Patients With AH
Next, we sought to identify serum markers that could distinguish between infection-
associated SIRS and SIRS without infection. For this purpose, we assessed potential serum 
biomarkers of infection and systemic inflammation. We first analyzed a biomarker of 
systemic inflammation (hsCRP) and a well-known biomarker of infection (procalcitonin) in 
a large subset of patients from the study cohort with AH (n = 89). The characteristics of this 
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subset of patients with AH were similar to those of the entire cohort (Supporting Table S3). 
Patients with alcoholic liver cirrhosis without AH (n=14) and healthy subjects (n=10) were 
included as control groups. Patients with AH had higher levels of procalcitonin (Fig. 2A) 
and hsCRP (Supporting Fig. S5A) at admission than patients with alcoholic liver cirrhosis 
and healthy controls. In AH, both procalcitonin and hsCRP levels correlated with disease 
severity, as assessed by the ABIC and MELD scores and modified Maddrey’s DF (data not 
shown). Moreover, procalcitonin serum levels were higher among patients who developed 
MOF during hospitalization (0.75 ng/mL versus 0.31 ng/mL in patients with and without 
MOF, respectively; P=0.001). There was also a trend for an association of MOF with hsCRP 
levels (mean hsCRP 3.28 mg/dL for patients who developed MOF versus 2.40 mg/dL for 
patients who did not develop MOF, P=0.058). Among patients with SIRS at admission, 
procalcitonin levels were higher in those with infection-associated SIRS than in those with 
SIRS without infection (0.89 ng/mL versus 0.35 ng/mL, P=0.015) (Fig. 2B). The best cutoff 
value to rule out infections (negative predictive value of 78.9%) was 0.25 ng/mL. For the 
diagnosis of infections in AH patients with SIRS, a cutoff of 0.45 ng/mL showed the best 
performance (positive predictive value of 83.3% and negative predictive value of 71%). 
Thus, 83.3% of patients with procalcitonin levels >0.45 ng/mL were infected at admission, 
while only 29% of patients with procalcitonin levels <0.45 ng/mL had an infection (P = 
0.012). These results suggest that procalcitonin could be a valuable biomarker to estimate 
the presence of infections in patients with AH and SIRS. High-sensitivity CRP was not able 
to discriminate between SIRS with and without infection (Supporting Fig. S5B).
We next analyzed serum levels of LPS, which is a marker of bacterial translocation and 
plays a role in the pathogenesis of alcoholic liver disease, in a subgroup of 50 patients with 
AH from the study cohort. Baseline characteristics of this subgroup were comparable with 
those of the entire cohort (Supporting Table S4). Levels of LPS did not discriminate 
between patients with or without SIRS, were similar in patients with SIRS without infection 
and infection-associated SIRS (data not shown), and predicted the development of MOF 
during hospitalization (Fig. 2C). Moreover, LPS serum levels correlated with the severity of 
AH (Fig. 2D) and predicted the development of inhospital infections. The incidence of in-
hospital infections was 59.1% among patients with LPS >1.30 EU/mL versus 28.6% among 
patients with LPS ≤1.30 EU/mL (P=0.03) (Fig. 2E). Interestingly, LPS at admission 
predicted the response to corticosteroids, assessed by the Lille score. All patients with LPS 
≤1.30 EU/mL responded to corticosteroid therapy, while 61.1% of patients with LPS >1.30 
EU/mL were nonresponders (P=0.006) (Fig. 2F). These results suggest that LPS levels do 
not discriminate between SIRS with and without infection, but can be clinically useful to 
identify nonresponders to corticosteroids.
We finally investigated if the three inflammatory markers (hsCRP, procalcitonin, and LPS) 
predict survival in AH. A detailed description of this analysis is given in the Supporting 
Information. All three biomarkers significantly predicted 90-day survival. In particular, 90-
day mortality was 14.9% in patients with procalcitonin <0.6 ng/mL versus 60% in patients 
with procalcitonin ≥0.6 ng/mL (P< 0.001) (Fig. 3A). Similarly, patients with LPS 
concentration ≤1.3 EU/mL also showed a very low mortality rate at 90 days (3.6%) 
compared to 50% mortality in patients with LPS >1.3 EU/mL (P< 0.001) (Fig. 3B).
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The mortality of patients with AH has not significantly improved in the last decades. 
Prednisolone, the main first-line therapy, was proposed in 1971 in an attempt to reduce 
hepatic inflammation, a common finding in AH. However, we recently found that severe 
hepatic infiltration of polymorphonuclear cells is associated with a favorable prognosis, 
suggesting that inflammation could drive hepatic regeneration in these patients.19 Moreover, 
an analysis of explants from patients with AH who underwent liver transplantation20 
revealed that severe AH is characterized by impaired regeneration, rather than 
inflammation.21 These data suggest that hepatic inflammation alone is not a good predictor 
of mortality in this setting. We therefore focused on the potential systemic effects of AH. 
This hypothesis was based on three main observations. First, patients with AH often show 
signs of SIRS at admission.22,23 Second, SIRS predicts the development of AKI in patients 
with AH, which is associated with decreased survival.5 Third, we consistently found that 
serum levels of powerful inflammatory mediators (e.g., interleukin-8, osteopontin, 
chemokine [C-C motif] ligand 20) correlate with their hepatic expression, suggesting that 
the liver is a source of circulating cytokines in AH.8,9,24 Our study clearly shows that the 
presence of SIRS is a major predictor of MOF and death in AH, suggesting that targeting 
systemic inflammation represents a novel therapeutic approach for these patients. In other 
diseases associated with sterile inflammation and SIRS, such as acute pancreatitis, the use of 
drugs that decrease the systemic inflammatory response has shown promising results.25
It is important to emphasize that all of the AH cases in our study were confirmed 
histologically. There are no reliable noninvasive methods to establish the diagnosis of AH. 
In our center, we have systematically performed transjugular biopsies in all patients with 
suspected AH; and in our experience, the diagnosis is confirmed in 75%–80% of patients. 
Alternative histologic diagnosis in patients with clinical suspicion of AH included 
decompensated alcoholic cirrhosis without superimposed AH, septic liver, ischemic 
hepatitis, and drug-induced liver injury. Therefore, our results may not apply to other causes 
of acute-on-chronic liver injury in patients with alcoholic liver disease.
The most striking result of this study is the demonstration that the presence of SIRS at 
admission is an important predictor of MOF and mortality in AH. This result has 
pathophysiological implications because it highlights the fact that extrahepatic consequences 
of AH are of paramount importance to a patient’s outcome. Moreover, we provide evidence 
that the existence of SIRS in these patients is not necessarily associated with an ongoing 
infection. In fact, in two-thirds of patients with SIRS criteria, an infection could not be 
detected by either clinical or microbiological criteria. It is difficult to accurately rule out 
infections in this setting because the sensibility of current culture techniques is limited. 
Therefore, the presence of SIRS in some of these patients could be secondary to an occult 
bacterial infection not identified with current diagnostic tests. However, it is also likely that 
SIRS in a subset of patients of this group is due to a sterile systemic inflammation. This may 
place AH within the growing group of liver pathologies, including acetaminophen toxicity 
and nonalcoholic steatohepatitis, in which sterile inflammation plays a prominent part.7,26 A 
key component of this is the release of extracellular damage–associated molecular pattern 
molecules, which increase inflammation within the liver and can also cause inflammation in 
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additional organs, resulting in a systemic inflammatory response. A large number of 
damage-associated molecular pattern molecules have been identified, and many, such as 
DNA, are excellent therapeutic targets.27 These data are also entirely consistent with recent 
experimental studies which have identified a role for pathways downstream of pattern 
recognition receptor activation, particularly the NOD-like receptor family, pyrin domain 
containing-3 inflammasome and interleukin-1β production.28 Discovering the mechanisms 
of sterile inflammation in AH will certainly lead to new pathophysiologically oriented 
therapies.
An important result of the study is that infections during hospitalization, but not at 
admission, are a major predictor of MOF at death. These results corroborate previous studies 
in patients with AH or cirrhosis.6,29,30 The impact of nosocomial infections is related to a 
more aggressive resistance profile of bacteria as well as to a more deteriorated liver 
function. Clinical trials assessing the beneficial effects of intestinal decontamination in 
patients with severe AH are under way.
Given that the presence of SIRS in AH can be related to an infectious episode or to sterile 
inflammation, it seems clinically relevant to find biomarkers capable of discriminating 
between these two entities. For this purpose, we analyzed a panel of biomarkers. Among 
them, we found that procalcitonin is useful in identifying bacterial infection as the cause of 
SIRS. This biomarker can be clinically useful because it can help in detecting patients who 
would benefit from early therapy with broad-spectrum antibiotics. This finding is consistent 
with a recent study showing that procalcitonin can be useful as a biomarker of infections in 
patients with AH and SIRS.31
Another relevant result from our study is that LPS serum levels at admission predict which 
patients will not respond to corticosteroids. There is mounting evidence that patients with 
alcoholic liver disease have profound dysbacteriosis and impaired tight junctions in the 
intestinal mucosa, favoring the translocation of gram-negative bacterial products such as 
LPS to the portal vein.32 Lipopolysaccharide signals through tolllike receptor-4 located in 
Kupffer cells and hepatic stellate cells, leading to hepatic inflammation and fibrosis.32,33 
Besides intrahepatic effects, increased circulating LPS levels could also play a role in the 
systemic inflammatory response and the complications of cirrhosis, such ascites, variceal 
bleeding, and encephalopathy34–36 Our results showing that procalcitonin and LPS predict 
MOF and death should be confirmed in independent cohorts. There is an ongoing pilot study 
assessing the beneficial effects of intestinal decontamination with rifaximin in patients with 
severe AH.37
In conclusion, our study demonstrates that the systemic inflammatory response, either 
caused by an ongoing infection or in the absence of an identifiable infection, is associated 
with the development of MOF and death in AH. Further studies should identify the main 
inflammatory mediators that cause this systemic response in order to develop targeted 
therapies.
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Ninety-day mortality according to (A) the presence of MOF, (B) the presence of SIRS, and 
(C) the SIRS-associated conditions.
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(A) Serum levels of procalcitonin according to the presence and severity of alcoholic liver 
disease, (B) serum levels of procalcitonin in patients with SIRS without infection versus 
infection-associated SIRS, (C) incidence of MOF according to serum levels of LPS, (D) 
serum levels of LPS according to the severity of AH assessed by ABIC score, (E) in-hospital 
infections, and (F) corticosteroid therapy response rate (assessed by the Lille score) 
according to serum levels of LPS.
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Ninety-day mortality according to the levels of (A) procalcitonin and (B) LPS.
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Table 1
Definitions of Single Organ Failure
Organ Definition
Liver failure SOFA ≥3 (serum bilirubin ≥6 mg/dL) or Maddrey’s DF >32
Renal failure Defined as AKI, according to the Acute Kidney Injury Network criteria
Nervous system failure SOFA ≥3 (Glasgow Coma Scale ≤9) or hepatic encephalopathy grade III or IV
Respiratory failure SOFA ≥3 (PaO2/FiO2 <200 and mechanically ventilated)
Circulatory failure SOFA ≥3 (use of norepinephrine, epinephrine, or dopamine [dopamine >5 μg/kg/min])
Coagulation failure SOFA ≥3 (platelet count <50,000/μL)
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Table 2
Characteristics of the Included Patients With Alcoholic Hepatitis (n=162)
Parameter Mean (95% CI) or n (%)
Clinical and epidemiological variables
 Gender (male) 115 (71%)
 Age (years) 50 (49–51)
 Proportion of patients with cirrhosis 118 (72.8%)
 SIRS at admission 75 (46.3%)
 MOF during hospitalization 58 (35.8%)
 Infection at admission 32 (19.8%)
 Infection during hospitalization 71 (43.8%)
 Time to in-hospital infection (days) 9 (7–10)
 90-day mortality 40 (24.7%)
Biochemical parameters at admission
 Creatinine (mg/dL) 1.1 (1.0–1.3)
 Bilirubin (mg/dL) 12 (10–13)
 AST (IU/L) 141 (126–157)
 ALT (IU/L) 54 (48–61)
 GGT (IU/L) 533 (430–637)
 Albumin (g/L) 27 (26–28)
 INR 1.7 (1.6–1.8)
Scoring systems at admission
 ABIC score 7.66 (7.44–7.89)
 ABIC class
  A 39 (24.1%)
  B 95 (58.6%)
  C 28 (17.3%)
 MELD score 21 (20–22)
 MELD >21 78 (48.1%)
 Maddrey’s DF 43 (38–48)
 Maddrey’s DF >32 90 (55.6%)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; INR, international 
normalized ratio.
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Table 3
Comparative of Patients With and Without MOF During Hospitalization
Variable Patients Without MOF (n=104) Patients With MOF (n=58) P
Gender (male), n (%) 69 (66.3%) 46 (79.3%) 0.081
Age (years), mean (95% CI) 49 (48–51) 52 (49–54) 0.122
ABIC score, mean (95% CI) 7.10 (6.87–7.34) 8.66 (8.32–9.00) <0.001
MELD score, mean (95% CI) 18 (17–19) 27 (25–29) <0.001
Maddrey’s DF, mean (95% CI) 32 (27–38) 62 (53–71) <0.001
Proportion of patients with cirrhosis, n (%) 72 (69.2%) 46 (79.3%) 0.167
SIRS at admission, n (%) 40 (38.5%) 35 (60.3%) 0.007
Infection at admission, n (%) 14 (13.5%) 18 (31.0%) 0.007
Infection during hospitalization, n (%) 26 (25%) 45 (77.6%) <0.001
Creatinine (mg/dL), mean (95% CI) 0.8 (0.7–0.9) 1.7 (1.3–2.1) <0.001
Bilirubin (mg/dL), mean (95% CI) 8 (7–10) 17 (15–20) <0.001
AST (IU/L), mean (95% CI) 143 (122–165) 137 (116–158) 0.850
ALT (IU/L), mean (95% CI) 54 (45–63) 54 (46–63) 0.354
GGT (IU/L), mean (95% CI) 617 (473–761) 384 (255–513) 0.003
Albumin (g/L), mean (95% CI) 28 (27–29) 25 (24–26) 0.002
INR, mean (95% CI) 1.6 (1.5–1.7) 2.0 (1.8–2.1) <0.001
90-day mortality, n (%) 4 (3.8%) 36 (62.1%) <0.001
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; INR, international 
normalized ratio.
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Table 4
Univariate and Multivariate Analyses of Factors Associated With MOF
Variable OR 95% CI P
Univariate analysis
 Age (years) 1.030 0.992–1.069 0.124
 Gender (male) 1.944 0.914–4.134 0.084
 Presence of cirrhosis 1.704 0.797–3.642 0.169
 SIRS at admission 2.435 1.261–4.701 0.008
 Infection at admission 2.893 1.311–6.384 0.009
 In-hospital infection 10.385 4.856–22.209 <0.001
 Creatinine (mg/dL) 4.647 2.109–10.240 <0.001
 Bilirubin (mg/dL) 1.121 1.075–1.169 <0.001
 AST (IU/P) 0.999 0.996–1.003 0.713
 ALT (IU/L) 1.001 0.993–1.008 0.961
 GGT (IU/L) 0.999 0.999–1.000 0.041
 Albumin (g/L) 0.890 0.828–0.957 0.002
 INR 5.351 2.414–11.860 <0.001
Multivariate model 1 (only variables at admission)
 SIRS at admission 2.687 1.129–6.395 0.025
 Infection at admission 1.591 0.590–4.289 0.358
 Creatinine (mg/dL) 2.508 1.146–5.491 0.021
 Bilirubin (mg/dL) 1.096 1.042–1.153 <0.001
 Albumin (g/L) 0.956 0.864–1.059 0.393
 INR 1.996 0.745–5.344 0.169
Multivariate model 2
 SIRS at admission 3.351 1.344–8.354 0.009
 In-hospital infection 6.585 2.562–16.924 <0.001
 Creatinine (mg/dL) 1.616 0.739–3.532 0.229
 Bilirubin (mg/dL) 1.095 1.037–1.157 0.001
 Albumin (g/L) 0.913 0.814–1.025 0.123
 INR 1.531 0.526–4.457 0.435
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; INR, international 
normalized ratio.
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